If confirmed in larger Phase 3 studies, they would represent some of the most significant weight loss outcomes observed with a pharmacological agent to date
doi: 10.2147/DDDT.S131892
As there was no unexplained heterogeneity, our results had no inconsistency
The platform emphasizes convenience, typically offering video visits within hours or days, a required monthly membership alongside flat medication pricing, and ongoing virtual follow-up care monitoring
3 These results make the drug class a life-and-death matter and not just weight loss drugs. We are optimistic the drug classs physiological effectiveness will eventually be borne out across a variety of medical indicationsand were optimistic about the drug manufacturers business prospects, as well
Despite declining sharply among lookalike respondents, emotional well-being improved among current GLP-1 users this month